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Comparison of COVID‑19 outcomes 
among shielded and non‑shielded 
populations
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Sean P. MacBride‑Stewart3, Patrick B. Mark4, Frances S. Mair1 & Jill P. Pell5*
Many western countries used shielding (extended self‑isolation) of people presumed to be at high‑risk 
from COVID‑19 to protect them and reduce healthcare demand. To investigate the effectiveness of 
this strategy, we linked family practitioner, prescribing, laboratory, hospital and death records and 
compared COVID‑19 outcomes among shielded and non‑shielded individuals in the West of Scotland. 
Of the 1.3 million population, 27,747 (2.03%) were advised to shield, and 353,085 (26.85%) were 
classified a priori as moderate risk. COVID‑19 testing was more common in the shielded (7.01%) and 
moderate risk (2.03%) groups, than low risk (0.73%). Referent to low‑risk, the shielded group had 
higher confirmed infections (RR 8.45, 95% 7.44–9.59), case‑fatality (RR 5.62, 95% CI 4.47–7.07) and 
population mortality (RR 57.56, 95% 44.06–75.19). The moderate‑risk had intermediate confirmed 
infections (RR 4.11, 95% CI 3.82–4.42) and population mortality (RR 25.41, 95% CI 20.36–31.71) but, 
due to their higher prevalence, made the largest contribution to deaths (PAF 75.30%). Age ≥ 70 years 
accounted for 49.55% of deaths. In conclusion, in spite of the shielding strategy, high risk individuals 
were at increased risk of death. Furthermore, to be effective as a population strategy, shielding criteria 
would have needed to be widely expanded to include other criteria, such as the elderly.
Early in the COVID-19 pandemic, a major concern was that the demand on health services would exceed capac-
ity in terms of hospitalisations, intensive care unit (ICU) admissions, and  ventilation1; hence, policy-makers 
sought interventions that could flatten the curve in severe cases to avoid hospitals becoming overwhelmed. It 
was assumed that sub-groups of the population would have worse prognosis and, therefore, contribute dispro-
portionately to adverse outcomes and healthcare  demands2.
Asian countries could implement case and contact  finding3. Early, widespread ‘test, trace, isolate’ strategies 
were made possible by their higher testing capacity and greater willingness to monitor and enforce compliance. 
In contrast, Europe and the USA were obliged to rely more heavily on non-pharmaceutical interventions in the 
first wave of the  pandemic3; general measures, such as physical distancing, face coverings, hand hygiene and 
lock-downs, designed to reduce transmission in the population as a whole, supplemented by shielding of those 
assumed to be at higher risk. Notably, Sweden, an outlier in not applying lock-down, nonetheless mandated 
 shielding4.
In the UK, a Vulnerable Patient List (Supplementary Table S1)5 was produced comprising two categories 
labelled high risk, highest risk or clinically extremely vulnerable and moderate risk, at risk or clinically vulnerable 
by various UK organisations. In this manuscript, they are referred to as shielded and moderate risk respectively, 
with the remaining population labelled low-risk. The shielded group received individual letters strongly recom-
mending they self-isolate over a protracted period; not leaving their homes and avoiding non-essential contact 
with household members. In Scotland, the shielded group was offered support through a number of interven-
tions; for example, 53% signed up to have food support, including home delivery of free food boxes and priority 
food  delivery6. Additional local schemes were set up to provide home delivery of  medicines6. Individuals in the 
shielded group were also eligible to apply for Statutory Sick Pay. In contrast, the moderate risk category was 
simply advised to be vigilant in adhering to general advice, for example, using hand sanitisers, wearing a face 
covering, and maintaining 2-m distance when entering indoor public spaces.
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The category definitions were based largely on expert opinion informed by our understanding of previous 
viruses and the need for better definitions has been highlighted and  discussed7,8. Studies are emerging of the 
risk factors associated with COVID-19 outcomes. Among two million UK community-based app users self-
reported heart disease, kidney disease, lung disease, diabetes and obesity were associated with self-reported 
hospital admission and respiratory support for COVID-199. Similarly, linkage of family practitioner records of 
17 million people in England reported a wide range of long-term conditions associated with in-hospital death 
from COVID-19 including: respiratory, heart, liver and kidney disease, diabetes, cancers, stroke and organ 
 transplantation10. Unfortunately, the investigators did not have access to deaths in the community. COVID-19 
risk scores are being developed in an attempt to improve identification of high risk individuals who could be 
advised to  shield11 but attempts to investigate the potential contribution of a shielding strategy to population-level 
outcomes and healthcare demands have so far been largely limited to mathematical  modelling12–20.
The aims of this study were to compare those classified, a priori, as high risk (and therefore advised to shield) 
and those classified as moderate and low-risk, in terms of their actual risk of COVID-19 infection and outcomes 
and the extent to which they accounted for COVID-19 related outcomes at a population level.
Results
Of the 1,315,071 people registered with family practitioners in NHS Greater Glasgow and Clyde in the West of 
Scotland, 26,747 (2.03%) were on the shielding list and 353,085 (26.85%) were classified, a priori, as moderate-
risk. Of the 26,747 shielded group, 18,147 (55.78%) had severe respiratory disease, 5349 (16.44%) were on 
immunosuppressive therapies, 2491 (7.66%) had specific cancers, 1245 (3.83%) had received organ transplants, 
475 (1.78%) were on renal dialysis, and less than five were pregnant and had severe heart disease. Of the 353,085 
classified as moderate-risk, 160,215 (45.38%) had hypertension, 151,865 (43.01%) had chronic lung disease, 
139,568 (39.53%) were ≥ 70 years of age, 64,358 (18.23%) had diabetes, 48,571 (13.81%) had heart disease, and 
1195 (0.34%) had a weakened immune system.
Shielded and moderate‑risk categories. Overall, 15,865 (1.21%) people were tested for COVID-19. 
The likelihood of being tested increased with age, was higher in women and the moderate-risk category and 
highest in the shielded group (Table 1). Overall, 3348 (0.25%) people had confirmed COVID-19 infection. The 
likelihood of laboratory-confirmed COVID-19 infection followed similar patterns as testing. It increased with 
age, was higher in women, was highest in the shielded group and lowest in the low-risk category (Table 2). After 
adjustment for sex and deprivation quintile, the risk of laboratory-confirmed infection remained higher in the 
moderate-risk category and highest in the shielded group (Fig. 1 and Supplementary Table S2).
Overall, 1661 people were hospitalised for COVID-19. Within the general population, hospitalisations 
increased with age but were comparable between men and women (Table 2). Hospitalisations were more common 
in the moderate-risk category and most common in the shielded group (Table 2), remaining so after adjustment 
for sex and deprivation (Fig. 1 and Supplementary Table S2). Overall, 122 people were admitted to ICU wards 
for COVID-19. ICU admissions were significantly more common among people aged 45–64 years of age than 
among older people (Table 2). Compared with the low-risk category, the shielded group were 18 times more 
likely to be hospitalised but only 4 times more likely to be admitted to ICU (Fig. 1 and Supplementary Table S2). 
Overall, 1027 (0.08%) people died from COVID-19. Within the general population, mortality increased with 
age but was similar in men and women (Table 2). Population mortality was higher in the moderate-risk category 
and highest in the shielded group (Table 2) and remained so after adjustment for sex and deprivation (Fig. 1 and 
Supplementary Table S2). Mortality in the community before/without admission to hospital was higher in the 
moderate-risk category  (RRmoderate/low [95% CI] 79.7 [39.9–159.0], p < 0.0001) and highest in the shielded group 
 (RRshielded/low [95% CI] 182.1 [86.5–383.3], p < 0.0001). A similar pattern was observed for mortality before/
without ICU admission  (RRmoderate/low [95% CI] 40.8 [29.0–57.4], p < 0.0001;  RRshielded/low [95% CI] 120.8 [83.0, 
175.9], p < 0.0001).
Among the sub-group with laboratory-confirmed (test-positive) COVID-19 infection, 1661 (49.6%) were 
hospitalised. Hospitalisations increased with age but were comparable between men and women (Table 3). The 
moderate-risk category was more likely to be hospitalised and the shielded group most likely (Table 3), remaining 
so after adjustment for age and deprivation (Fig. 2 and Supplementary Table S3). Among those with laboratory-
confirmed infection, ICU admissions were more common in men and more common in people aged 45–64 years 
than those older (Table 3). Low-risk cases were more likely to be admitted to ICU than the moderate-risk and 
shielded groups (Fig. 2). Among the sub-group with clinically-confirmed (test-positive or COVID-19 related 
death) COVID-19 infection, 1027 (26.70%) died (Table 3). Case-fatality increased by age and was higher in men 
than women. It was lowest in the low-risk category but not significantly different between the moderate-risk 
and shielded groups  (RRshielded/moderate [95% CI] 1.12 [0.96–1.31], p = 0.14) (Fig. 2 and Supplementary Table S3).
The shielded group accounted for 7.62% of laboratory-confirmed COVID-19 infections, 12.70% of COVID-19 
hospitalisations, 2.69% of ICU admissions and 13.22% of COVID-19 related deaths (Supplementary Table S4). 
The corresponding figures for the moderate-risk category were 42.06%, 53.28%, 22.96% and 75.30%. To prevent 
at least 80% of deaths, 28.8% of the population would have had to receive the current level of shielding including 
those with five criteria classified as moderate- risk at the time of the study (Supplementary Figure S1).
Individual risk criteria. Due to insufficient numbers, the individual risk criteria models could not be run 
for pregnant women with severe heart disease or for COVID-19 related ICU admission in the shielded category. 
All the remaining individual risk criteria were associated with higher likelihood of being tested for COVID-19 
(Table 1), laboratory-confirmed infection (Table 2), hospitalisation, population mortality (Fig. 1 and Supple-
mentary Table S2) and case-fatality (Fig. 2 and Supplementary Table S3) independent of sex and deprivation. 
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Among the moderate-risk category criteria, age ≥ 70 years and weakened immune system had risks of population 
mortality (Fig. 1 and Supplementary Table S2) and case-fatality (Fig. 2 and Supplementary Table S3) at least as 
high as the overall shielded group. Apart from the 0.13% of people with relevant rare diseases or inborn errors of 
metabolism and 1.78% on renal dialysis, the strongest associations were observed for those aged ≥ 70 years who 
were eight times as likely to have confirmed infection (Fig. 1 and Supplementary Table S2); seven times as likely 
to die following confirmed infection (Fig. 2 and Supplementary Table S3); and 74 times as likely to die overall 
(Fig. 1 and Supplementary Table S2) compared with the low-risk category. Being ≥ 70 years of age accounted 
for 17.81% of confirmed COVID-19 infections, 22.19% of COVID-19 related hospitalisations, and 49.55% of 
COVID-19 related deaths (Supplementary Table S4). Among those hospitalised for COVID-19, the likelihood 
of ICU admission was significantly lower for all individual risk criteria in the moderate-risk category, other than 
diabetes (Fig. 2 and Supplementary Table S3). In particular, hospitalised patients ≥ 70 years of age were 14 times 
less likely to be admitted to ICU than low-risk hospitalised patients (Fig. 2 and Supplementary Table S3).
Discussion
The 2.03% of people advised to shield were, nonetheless, eight times more likely to have confirmed infections 
than the low-risk category, five times more likely to die following confirmed infection and 49 times more likely 
to die from COVID-19 overall. Whilst selective testing might explain the first outcome, it does not explain higher 
overall mortality which suggests that the shielding strategy was not as effective as was hoped.





N = 1,299,206 N = 15,865
n (%) n (%)
Age group (years) < 0.0001
0–24 355,238 (99.49) 1822 (0.51)
25–44 410,408 (99.22) 3247 (0.78)
45–64 340,268 (98.65) 4660 (1.35)
≥ 65 193,292 (96.92) 6136 (3.08)
Sex < 0.0001
Male 654,041 (99.01) 6569 (0.99)
Female 645,165 (98.58) 9296 (1.42)
Deprivation quintile < 0.0001
1 (most deprived) 461,672 (98.67) 6211 (1.33)
2 230,402 (98.75) 2921 (1.25)
3 194,702 (98.90) 2175 (1.10)
4 173,456 (98.93) 1883 (1.07)
5 (most affluent) 238,974 (98.89) 2675 (1.11)
Risk category < 0.0001
Low 928,420 (99.27) 6819 (0.73)
Moderate 345,913 (97.97) 7172 (2.03)
Shielded 24,873 (92.99) 1874 (7.01)
Moderate risk criteria
Chronic respiratory disease 149,325 (98.33) 2540 (1.67) < 0.0001
Heart disease 46,728 (96.21) 1843 (3.79) < 0.0001
Hypertension 156,286 (97.55) 3929 (2.45) < 0.0001
Diabetes 62,482 (97.09) 1876 (2.91) < 0.0001
Weakened immune system 1140 (95.40) 55 (4.60) < 0.0001
≥ 70 years of age 134,305 (96.23) 5263 (3.77) < 0.0001
Shielded criteria
Severe respiratory disease 17,146 (94.48) 1001 (5.52) < 0.0001
Specific cancers 2075 (83.30) 416 (16.70) < 0.0001
Pregnant with severe heart disease < 5 0 –
Immunosuppressive therapy 5028 (94.00) 321 (6.00) < 0.0001
Solid organ transplant 1149 (92.29) 96 (7.71) < 0.0001
Rare diseases and inborn errors of metabolism 1623 (91.95) 142 (8.05) < 0.0001
Renal dialysis 305 (64.21) 170 (35.79) < 0.0001
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Confirmed COVID-19 infection COVID-19 hospitalisation COVID-19 ICU admission COVID-19 mortality
Negative test/








N = 1,311,723 N = 3,348 N = 1,313,410 N = 1661 N = 1,314,949 N = 122 N = 1,314,044 N = 1027
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Age group 
(years) < 0.0001 < 0.0001 0.0005 < 0.0001





























Male 659,203 (99.79) 1407 (0.21) < 0.0001
659,781 
(99.87) 829 (0.13) 0.81
660,525 
(99.99) 85 (0.01) < 0.0001
660,092 
(99.92) 518 (0.08) 0.92
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(99.70) 451 (0.30) 0.0005
151,618 
(99.84) 247 (0.16) < 0.0001
151,853 
(99.99) 12 (0.01) 0.65
151,812 
(99.97) 53 (0.03) < 0.0001
Heart 




(99.41) 948 (0.59) < 0.0001
159,670 
(99.66) 545 (0.34) < 0.0001
160,189 
(99.98) 26 (0.02) 0.003
159,991 
(99.86) 224 (0.14) < 0.0001








(98.96) 1,453 (1.04) < 0.0001
138,701 
(99.38) 867 (0.62) < 0.0001
139,560 
(99.99) 8 (0.01) 0.19
138,690 





17,981 (99.09) 166 (0.91) < 0.0001 18,012 (99.26) 135 (0.74) < 0.0001 18,146 (99.99) < 5 – 18,059 (99.52) 88 (0.48) < 0.0001
Specific 








5285 (98.80) 64 (1.20) < 0.0001 5299 (99.07) 50 (0.93) < 0.0001 5346 (99.94) < 5 – 5324 (99.53) 25 (0.47) < 0.0001
Solid organ 
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One quarter of the population were classified as moderate-risk and not advised to shield. Nonetheless, they 
were four times more likely to have confirmed infections than the low-risk category, five times more likely to 
die following confirmed infection and 25 times more likely to die overall, suggesting that, where shielding is 
employed, the shielding criteria should be expanded. In particular, older age needs to be considered since the 
elderly are both at high individual risk and contribute significantly to population burden due to their relatively 
high numbers. A survey of 1695 rheumatology patients reported that the shielded sub-group has slightly lower 
risk of COVID-19 infection than the non-shielded sub-group (3.0% vs 4.1%) but the difference did not reach 
statistical  significance21. In spite of people in the shielded and moderate-risk categories having poorer prognosis, 
they were less likely to be admitted to ICU following hospitalisation for COVID-19, especially patients ≥ 70 years. 
This finding reinforces the importance of protection in those with the worst prognosis.
Our finding that 26.85% of people satisfied the moderate-risk criteria is consistent with limited existing 
evidence. A study linking English primary and secondary care records on 3.9 million people reported that 20% 
of population satisfied similar  criteria22. Similarly, analysis of the Global Burden of Diseases Study estimated 
that 22% of the global population are at increased risk of severe COVID-19  disease19. A USA study using data 
from the Behavioral Risk Factor Surveillance System reported that 45.4% of 444,649 adults had one or more 
of a longer list of morbidities that may be associated with higher risk from COVID-1923. Another USA study 
estimated that 14.2% of participants in the National Health Interview Survey had more than two-fold risk and 
1.6% had more than tenfold  risk24.
The evidence on COVID-19 related complications among those classified as high risk, and therefore advised to 
shield, has mainly come from case series and expert opinion. Case series found higher COVID-19 related compli-
cations among organ transplant  recipients25,26, patients receiving chemotherapy, radiotherapy or immunotherapy 
for  cancer27,28, and patients with haematological  cancers29. Systematic review suggested higher COVID-19 com-
plication risk among COPD patients, but the effect of COPD severity was not  investigated30. Patients with cystic 
fibrosis and sickle cell disease were classified as high risk based on expert  opinion31,32. While pregnant women 
with COVID-19 were found to have higher risk of poor maternal and perinatal  outcomes33,34, outcomes were 
not investigated specifically for pregnant women with heart disease. There was no evidence of worse COVID-19 
related complications among patients on  immunosuppressants35. A large community study in England found 
strong association between severe asthma (hazard ratio 1.25) and COVID-19 related mortality but did not 
investigate the risk of COVID-19 infection or  hospitalisation36.
In common with previous  studies37, we demonstrated that age was a major individual-level risk factor for 
death. Additionally, we showed it is important at the population level with 49.55% of deaths attributable to 
age ≥ 70 years. The higher mortality in the elderly was mediated in part by higher case-fatality but they also had a 
higher incidence of infection, possibly due to transmission within care homes. Lower ICU admissions following 
hospitalisation for COVID-19 may have contributed to their higher case-fatality. Previous studies have reported 
that men are at higher risk of COVID-197. Our study demonstrated they are less likely to be tested for COVID-19, 
have confirmed infection, and be hospitalised. They have comparable overall mortality from COVID-19, due to 
their lower incidence, but their case-fatality is higher.
Confirmed COVID-19 infection COVID-19 hospitalisation COVID-19 ICU admission COVID-19 mortality
Negative test/








N = 1,311,723 N = 3,348 N = 1,313,410 N = 1661 N = 1,314,949 N = 122 N = 1,314,044 N = 1027




1729 (97.96) 36 (2.04) < 0.0001 1741 (98.64) 24 (1.36) < 0.0001 1764 (99.94) < 5 – 1744 (98.81) 21 (1.19) < 0.0001
Renal 
dialysis 445 (93.68) 30 (6.32) < 0.0001 457 (96.21) 18 (3.79) < 0.0001 475 (100.00) 0 (0.00) – 468 (98.53) 7 (1.47) < 0.0001
Table 2.  Crude, population-level COVID-19 outcomes by sociodemographic characteristics, risk category and 
risk criteria. N number; IEM inborn errors of metabolism.
Figure 1.  Associations* between risk categories and risk criteria and population-level COVID-19 outcomes. 
*Adjusted for sex, deprivation quintile, and other risk categories. RR relative risk; CI confidence interval; IEM 
inborn errors of metabolism.
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This study adds to the existing evidence of the possible effectiveness of a shielding strategy which is largely 
limited to mathematical modelling of population effects based on  assumptions12–20. The modelling papers con-
cluded that shielding could potentially reduce deaths and demand for ICU beds, subject to a range of parameters 
including the transmission rate, proportion shielding, and baseline case-fatality rate, but could not reduce to 
reproduction rate to below 1 in the absence of other non-pharmaceutical interventions. In Scotland, prior to 
the introduction of shielding, those individuals subsequently advised to shield accounted for 40% of COVID-
19  deaths8. However, an unpublished study reported that, following the introduction of shielding, the rate of 
decline in COVID-19 incidence in the shielding group was comparable to the general  population38, suggesting 
Table 3.  Crude COVID-19 outcomes among confirmed cases by sociodemographic characteristics, risk 
category and risk criteria. N number; IEM inborn errors of metabolism. a Laboratory-confirmed (test-positive) 
COVID-19 cases. b Clinically-confirmed (test-positive or COVID-19 on death certificate) COVID-19 cases.
COVID-19 hospitalisation
N =  3348a
COVID-19 ICU admission
N =  3348a
COVID-19 case-fatality







N = 1687 N = 1661 N = 3226 N = 122 N = 2819 N = 1027
n (%) n (%) n (%) n (%) n (%) n (%)
Age group 
(years) < 0.0001 < 0.0001 < 0.0001
0–24 97 (83.62) 19 (16.38) 116 (100.00) 0 116 (100.00) 0 (0.00)
25–44 410 (76.92) 123 (23.08) 520 (97.74) 12 (2.26) 526 (98.50) 8 (1.50)
45–64 553 (51.59) 519 (48.41) 990 (92.35) 82 (7.65) 1003 (91.77) 90 (8.23)
≥ 65 630 (38.65) 1000 (61.35) 1600 (98.28) 28 (1.72) 1174 (55.83) 929 (44.17)
Sex < 0.0001
Male 579 (41.12) 829 (58.88) < 0.0001 1322 (93.96) 85 (6.04) < 0.0001 1105 (68.08) 518 (31.92)
Female 1108 (57.11) 832 (42.89) 1904 (98.09) 37 (1.91) 1717 (77.10) 509 (22.90)
Deprivation 
quintile < 0.0001 0.29 0.0004
1 (most 
deprived) 566 (43.44) 737 (56.56) 1250 (96.08) 51 (3.92) 1046 (70.34) 441 (29.66)
2 332 (54.07) 282 (45.93) 592 (96.57) 21 (3.43) 531 (78.90) 142 (21.10)
3 235 (50.98) 226 (49.02) 438 (95.01) 23 (4.99) 394 (72.03) 153 (27.97)
4 204 (51.00) 196 (49.00) 390 (97.50) 10 (2.50) 341 (72.40) 130 (27.60)
5 (most affluent) 353 (61.61) 220 (38.39) 556 (97.03) 17 (2.97) 507 (75.90) 161 (24.10)
Risk category < 0.0001 0.0001 < 0.0001
Low 791 (66.41) 400 (33.59) 1125 (94.54) 65 (5.46) 1130 (93.08) 84 (6.92)
Moderate 828 (44.54) 1031 (55.46) 1807 (97.20) 52 (2.80) 1485 (64.90) 803 (35.10)
Shielded 71 (23.59) 230 (76.41) 294 (98.33) 5 (1.67) 204 (59.30) 140 (40.70)
Moderate risk criteria
Chronic respira-
tory disease 205 (45.35) 247 (54.65) 0.02 439 (97.34) 12 (2.66) 0.29 420 (88.79) 53 (11.21) < 0.0001
Heart disease 149 (37.72) 246 (62.28) < 0.0001 388 (98.23) 7 (1.77) 0.049 330 (74.16) 115 (25.84) 0.7
Hypertension 404 (42.57) 545 (57.43) < 0.0001 922 (97.26) 26 (2.74) 0.10 836 (78.87) 224 (21.13) < 0.0001
Diabetes 161 (35.31) 295 (64.69) < 0.0001 432 (94.95) 23 (5.05) 0.11 398 (80.73) 95 (19.27) < 0.0001
Weakened 
immune system 2 (16.67) 10 (83.33) 0.04 12 (100.00) 0 – 6 (50.00) 6 (50.00) 0.13
 ≥ 70 years of age 587 (40.37) 867 (59.63) < 0.0001 1445 (99.45) 8 (0.55) < 0.0001 1035 (54.10) 878 (45.90) < 0.0001
Shielding criteria
Severe respira-
tory disease 33 (19.64) 135 (80.36) < 0.0001 165 (99.40) < 5 – 111 (55.78) 88 (44.22) < 0.0001
Specific cancers 10 (25.64) 29 (74.36) 0.003 39 (100.00) 0 – 27 (62.79) 16 (37.21) 0.16
Pregnant, severe 
heart disease – – – – – – – – –
Immunosup-
pressive therapy 14 (21.88) 50 (78.12) < 0.0001 61 (95.31) < 5 – 42 (62.69) 25 (37.31) 0.07
Solid organ 
transplant 2 (11.76) 15 (88.24) 0.003 16 (94.12) < 5 - 11 (61.11) 7 (38.89) 0.37
Rare diseases 
and IEM 12 (33.33) 24 (66.67) 0.06 35 (97.22) < 5 – 23 (52.27) 21 (47.73) 0.003
Renal dialysis 12 (40.00) 18 (60.00) 0.33 30 (100.00) 0 – 23 (76.67) 7 (23.33) 0.83
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that the decline was most likely due to the suite of non-pharmaceutical interventions introduced at that time, 
rather than shielding  specifically8,38.
Ours was a large-scale, unselected general population study. The data cover a period when shielding was 
in place. Linkage of family practitioner, laboratory, hospital and death data enabled us to examine a range of 
COVID-19 outcomes and study a range of exposure variables including the overall risk categories and their 
individual criteria. The datasets were linked using exact, rather than probabilistic, matching. We were able to 
adjust for potential sociodemographic confounders. This is important since, in spite of eligibility for Statutory 
Sick Pay, the financial impact of shielding was greater among people on short, fixed term or zero hours contracts, 
in self-employment, or unable to work from home, and compliance with shielding was worse in more deprived 
 households39. The exposure data were collected prior to the outcomes occurring avoiding potential reverse causa-
tion and recall or recording bias. Our analysis of potential risk factors was restricted to those used as criteria for 
shielding and moderate-risk at the time of the study. We did not have data on ethnicity and rurality and there 
may be other unmeasured confounders such as exposure to health and social care workers and compliance with 
 restrictions20,40. The list of people meeting the shielding and moderate-risk criteria was extracted at the study 
mid-point; therefore, some people may have been misclassified prior to and after this date.
This is a pragmatic study that evaluates the effectiveness of shielding as delivered and supported in Scotland 
over the first wave of COVID-19. Shielding was recommended but not monitored or enforced. Forty one percent 
of people advised to shield in Scotland reported stringently following shielding guidance and 21% reported they 
were unable to comply for a variety of reasons such as supporting other household members (e.g. only driver), 
caring for pets, avoiding domestic abuse, or undertaking essential  chores39. Many also reported difficulties social 
distancing within their home due to shared facilities or carer roles. Our findings are representative of Glasgow 
and Greater Clyde area but may be less so for other areas or countries. In particular, the effectiveness of shielding 
may be different in countries with different levels of support, monitoring or compliance.
Our findings suggest that attempts to shield those at highest risk have not been as successful as hoped, with 
those advised to shield experiencing higher rates of infection and death. Since this group was also less likely 
to be admitted to ICU, protecting them from infection is essential. For shielding to be effective as a population 
level strategy, the current criteria would need to be expanded, since three-quarters of deaths were associated 
with moderate-risk criteria for which shielding had not hitherto been recommended. In our study, more than 
one-quarter of the general population would have needed to be effectively shielded to prevent over 80% of 
deaths. Since this is unlikely to be acceptable at a time when governments are under pressure to avoid further 
lock-downs, shielding is probably best viewed as an intervention to protect individuals, to be used alongside 
other population-wide interventions such as physical distancing, face coverings and hand hygiene.
Methods
This was a general population cohort study of all 1.3 million residents of NHS GGC in the West of Scotland 
between March and May 2020. In Scotland, shielding was recommended from the start of pandemic, throughout 
the whole study period, until end of July 2020. The Community Health Index (CHI), a unique identifier attached 
to all Scottish health records, enabled individual-level record linkage of nine databases: Community Health 
Index (CHI) register, NHS GGC Shielding List, Egton Medical Information Systems (EMIS) and Vision, Elec-
tronic Communication of Surveillance in Scotland (ECOSS), Prescribing Information System (PIS), Strathclyde 
Electronic Renal Patient Record (SERPR), Rapid Preliminary Inpatient Data (RAPID), and death certificates.
The CHI register provided sociodemographic information (age, sex, area socioeconomic deprivation). Dep-
rivation was measured using the Scottish Index of Multiple Deprivation (SIMD), derived from seven domains—
income, education, health, employment, crime, housing, and access to services—and categorised into general 
population quintiles. ECOSS collects laboratory data on infectious diseases, including test date and result. 
Albasoft software extract data from the family practitioner electronic health record systems EMIS and Vision, 
and PIS collects data on medications prescribed by family practitioners. SERPR records data on renal replace-
ment therapy and transplantation. RAPID collects real-time data on hospitalisation, including dates of admis-
sion and discharge, and type of ward, and the Scottish Morbidity Record 01 (SMR01) subsequently records the 
relevant disease codes. Death certificates provide the date and cause of all deaths, whether in-hospital or in the 
Figure 2.  Associations* between risk categories and risk criteria and COVID-19 outcomes among confirmed 
cases. *Adjusted for sex, deprivation quintile, and other risk categories. RR relative risk; CI confidence interval; 
IEM inborn errors of metabolism.
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community. Follow-up data were available until the end of May 2020, before the shielding recommendation 
was lifted.
Supplementary Table S1 lists the criteria for the shielded and medium risk categories applied at the time of 
data extraction. All remaining patients were categorised as low-risk. The Scottish list of high-risk individuals 
is compiled centrally, and regularly updated, using family practitioner, hospital admission, disease registry and 
medication data. Family practitioners check the completeness and accuracy of the list before letters, recommend-
ing shielding, are sent to patients. The NHS GGC Shielding List we used contains the validated data including 
the criterion satisfied. We ascertained moderate risk individuals using Albasoft extraction of EMIS and Vision 
data, and PIS data.
Separate models were conducted by overall risk category (low-risk, moderate-risk or shielded) and by the 
individual criteria for the moderate-risk and shielded categories. The four general population outcomes investi-
gated were: confirmed COVID-19 infection; COVID-19 related hospitalisation; COVID-19 related ICU admis-
sion; COVID-19 related mortality. The three outcomes investigated among those with confirmed infection 
were: COVID-19 related hospitalisation; COVID-19 related ICU admission; and COVID-19 related case fatality.
Laboratory-confirmed cases were defined as positive PCR test. Clinically-confirmed cases were defined as 
either positive PCR test or death from COVID-19 without testing. COVID-19 related deaths were defined as 
International Classification of Diseases 10th revision (ICD-10) code U07.1 or U07.2 recorded on the death 
certificate. COVID-related hospitalisation was defined as an SMR01 hospitalisation record with an ICD code 
U07.1 or U07.2 or, for more recent admissions, a RAPID hospitalisation record plus positive PCR test taken 
between two weeks before and two days after hospitalisation. ICU admission during such hospitalisations was 
assumed to be COVID-related.
Sociodemographic characteristics were compared by risk category using chi-square tests. Poisson regression 
models with robust standard errors were used to compare risk ratios (RR) for the shielded and moderate-risk 
categories referent to the low-risk category. Applying Poisson models to binary outcomes can be subject to an 
under-dispersion problem. This was overcome by deriving robust ‘sandwich’ standard  errors41. The models were 
run univariately; then adjusted for sex, SIMD quintile, and other risk categories as potential confounders. Age was 
not included as a covariate because it was a moderate-risk criterion. The models were re-run using the individual 
criteria for the shielded and moderate-risk categories as the exposure variables, referent to the low-risk category.
Population attributable fractions (PAFs)42 were calculated, from prevalence and adjusted RR, to determine 
the proportion of each outcome that could be attributed to being shielded and moderate-risk, as well as the 
proportion due to each individual criterion. The PAFs of individual criteria were proportionally calibrated so 
that their sum equated to the overall PAF of the relevant risk category. PAF confidence intervals were estimated 
using bootstrapping (× 1000) taking account of the variance for prevalence and RRs.
Ethical approvals. The study was approved by the NHS GGC Primary Care Information Sharing Group 
and the NHS GGC Local Privacy Advisory Committee (Reference GSH/20RM005) and was covered by the 
generic Safe Haven Research Ethics Committee approval (GSH20RM005_COVID_Community). Explicit con-
sent was not feasible to obtain as the data custodians provided us with an anonymised extract of secondary 
data. Requirement for consent was waived by the Safe Haven Research Ethics Committee, as part of the study 
approval, on the basis of adequate data protection safeguards including: anonymisation, analysis with a safe 
haven environment, information governance training, disclosure control and signed agreements. The study has 
been performed in accordance with the Declaration of Helsinki.
Received: 30 October 2020; Accepted: 9 July 2021
References
 1. Willan, J., King, A. J., Jeffery, K. & Bienz, N. Challenges for NHS hospitals during covid-19 epidemic. BMJ 368, (2020).
 2. Tulloch, O. Shielding People at High Risk of Severe Outcomes from COVID-19. https:// opend ocs. ids. ac. uk/ opend ocs/ bitst ream/ 
handle/ 20. 500. 12413/ 15286/ SSHAP COVID- 19 Brief Shielding.pdf (2020).
 3. ACAPS. COVID19 a Global Joint Response. https:// www. acaps. org/ proje cts/ covid- 19 (2020).
 4. Swedish Civil Contingencies Agency (MSB). National ban on visiting elderly homes. (2020).
 5. Public Health England. Guidance on shielding and protecting people who are clinically extremely vulnerable from COVID-19. 
(2020).
 6. Public Health Scotland. Covid-19 Shielding Programme (Scotland) Rapid Evaluation Full Report. https:// www. publi cheal thsco tland. 
scot/ media/ 2949/ covid- 19- shiel ding- progr amme- scotl and- rapid- evalu ation- full- report. pdf (2021).
 7. Lipsitch, M., Swerdlow, D. L. & Finelli, L. Defining the epidemiology of Covid-19—Studies needed. N. Engl. J. Med. 382, 1194–1196 
(2020).
 8. Williams, A. N. Respectful disagreement: The covid-19 shielding list. BMJ 372, (2021).
 9. Lochlainn, M. N. et al. Key predictors of attending hospital with COVID19: An association study from the COVID Symptom 
Tracker App in 2,618,948 individuals. medRxiv 2020.04.25.20079251. https:// doi. org/ 10. 1101/ 2020. 04. 25. 20079 251 (2020).
 10. Williamson, E. J. et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 584, 430–436 (2020).
 11. Wynants, L. et al. Prediction models for diagnosis and prognosis of covid-19 infection: Systematic review and critical appraisal. 
BMJ 369, m1328 (2020).
 12. Vlas, S. J. de & Coffeng, L. E. A phased lift of control: a practical strategy to achieve herd immunity against Covid-19 at the country 
level. medRxiv. https:// doi. org/ 10. 1101/ 2020. 03. 29. 20046 011 (2020).
 13. Keeling, M. J. et al. Predictions of COVID-19 dynamics in the UK: Short-term forecasting and analysis of potential exit strategies. 
PLoS Comput. Biol. 17, e1008619 (2021).
9
Vol.:(0123456789)
Scientific Reports |        (2021) 11:15278  | https://doi.org/10.1038/s41598-021-94630-6
www.nature.com/scientificreports/
 14. McKeigue, P. M. & Colhoun, H. M. Evaluation of ‘stratify and shield’ as a policy option for ending the COVID-19 lockdown in 
the UK. medRxiv. https:// doi. org/ 10. 1101/ 2020. 04. 25. 20079 913 (2020).
 15. Bunnik, B. Van, Woolhouse, M. & van Bunnik, B. A. D. Segmentation and shielding of the most vulnerable members of the popula-
tion as elements of an exit strategy from COVID-19 lockdown. medrxiv. https:// doi. org/ 10. 1101/ 2020. 05. 04. 20090 597 (2020).
 16. Weitz, J. S. et al. Modeling shield immunity to reduce COVID-19 epidemic spread. Nat. Med. 26, 849–854 (2020).
 17. Neufeld, Z., Khataee, H. & Czirok, A. Targeted adaptive isolation strategy for COVID-19 pandemic. Infect. Dis. Modell. 357–61. 
https:// doi. org/ 10. 1101/ 2020. 03. 23. 20041 897 (2020).
 18. Acemoglu, D., Chernozhukov, V., Werning, I. & Whinston, M. Optimal Targeted Lockdowns in a Multi-Group SIR Model. https:// 
doi. org/ 10. 3386/ w27102 (2020).
 19. Clark, A. et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying 
health conditions in 2020: A modelling study. Lancet Glob. Heal. https:// doi. org/ 10. 1016/ S2214- 109X(20) 30264-3 (2020).
 20. Davies, N. G. et al. Effects of non-pharmaceutical interventions on COVID-19 cases, deaths, and demand for hospital services in 
the UK: A modelling study. Lancet Public Heal. https:// doi. org/ 10. 1016/ S2468- 2667(20) 30133-X (2020).
 21. Cleaton, N. et al. The impact of COVID-19 on rheumatology patients in a large UK centre using an innovative data collection 
technique: Prevalence and effect of social shielding. Rheumatol. Int. 1–8 (2021).
 22. Banerjee, A. et al. Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions 
and age: A population-based cohort study. Lancet https:// doi. org/ 10. 1016/ s0140- 6736(20) 30854-0 (2020).
 23. Adams, M. L., Katz, D. L. & Grandpre, J. Population based estimates of comorbidities affecting risk for complications from COVID-
19 in the US. medRxiv. https:// doi. org/ 10. 1101/ 2020. 03. 30. 20043 919 (2020).
 24. Jin, J., Agarwala, N., Kundu, P. & Chatterjee, N. Estimating the size of high-risk populations for COVID-19 mortality across 442 
US cities. https:// doi. org/ 10. 1101/ 2020. 05. 27. 20115 170 (2020).
 25. Pereira, M. et al. COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. Am. J. Transplant https:// 
doi. org/ 10. 1111/ AJT. 15941 (2020).
 26. Fernández-Ruiz, M. et al. COVID-19 in solid organ transplant recipients: A single-center case series from Spain. Am. J. Transplant 
https:// doi. org/ 10. 1111/ AJT. 15929 (2020).
 27. Zhang, L. et al. Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within 
Wuhan, China. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. https:// doi. org/ 10. 1016/J. ANNONC. 2020. 03. 296 (2020).
 28. Dai, M. et al. Patients with cancer appear more vulnerable to SARS-COV-2: A multi-center study during the COVID-19 outbreak. 
Cancer Discov. https:// doi. org/ 10. 1158/ 2159- 8290. CD- 20- 0422 (2020).
 29. He, W. et al. COVID-19 in persons with haematological cancers. Leukemia 1–9. https:// doi. org/ 10. 1038/ s41375- 020- 0836-7 (2020).
 30. Yang, J. et al. Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: A systematic review and meta-analysis. 
Int. J. Infect. Dis. 94, (2020).
 31. Colombo, C. et al. Impact of COVID-19 on people with cystic fibrosis. Lancet Respir. Med. 8, e35–e36 (2020).
 32. Rodriguez-Morales, A. et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel 
Med. Infect. Dis. https:// doi. org/ 10. 1016/J. TMAID. 2020. 101623 (2020).
 33. Di Mascio, D. et al. Outcome of coronavirus spectrum infections (SARS, MERS, COVID 1–19) during pregnancy: A systematic 
review and meta-analysis. Am. J. Obstet. Gynecol. MFM https:// doi. org/ 10. 1016/J. AJOGMF. 2020. 100107 (2020).
 34. Elshafeey, F. et al. A systematic scoping review of COVID-19 during pregnancy and childbirth. Int. J. Gynaecol. Obstet. https:// doi. 
org/ 10. 1002/ IJGO. 13182 (2020).
 35. Minotti, C., Tirelli, F., Barbieri, E., Giaquinto, C. & D, D. How is immunosuppressive status affecting children and adults in SARS-
CoV-2 infection? A systematic review. J. Infect. S0163–4453, (2020).
 36. The OpenSAFELY et al. OpenSAFELY: Factors associated with COVID-19-related hospital death in the linked electronic health 
records of 17 million adult NHS patients. medRxiv 2020.05.06.20092999. https:// doi. org/ 10. 1101/ 2020. 05. 06. 20092 999 (2020).
 37. Ho, F. K. et al. Is older age associated with COVID-19 mortality in the absence of other risk factors? General population cohort 
study of 470,034 participants. PLoS ONE 15, e0241824 (2020).
 38. McKeigue, P. M. et al. Relation of severe COVID-19 in Scotland to transmission-related factors and risk conditions eligible for 
shielding support: REACT-SCOT case-control study. medRxiv (2021).
 39. Delvaux, J. & Marosi, D. Covid-19 Shielding Programme (Scotland) Impact and Experience Survey. https:// www. publi cheal thsco 
tland. scot/ downl oads/ covid- 19- shiel ding- progr amme- scotl and- impact- and- exper ience- surve y/? utm_ source= websi tenew s& utm_ 
medium= newsi tem& utm_ campa ign= shiel dings urvey (2020).
 40. Besançon, L., Meyerowitz‐Katz, G., Chini, E. Z., Fuchs, H. & Flahault, A. Challenges in determining causality: An ongoing critique 
of Bendavid et al’s “Assessing mandatory stay‐at‐home and business closure effects on the spread of COVID‐19.” Eur. J. Clin. Invest. 
e13599 (2021).
 41. Zou, G. A modified Poisson regression approach to prospective studies with binary data. Am. J. Epidemiol. 159, 702–706 (2004).
 42. Vander Hoorn, S., Ezzati, M., Rodgers, A., Lopez, A. D., & Murray, C. J. Estimating Attributable Burden of Disease from Exposure 
and Hazard Data. Comparative Quantification of health risks: Global and Regional Burden of Disease Attributable to Selected Major 
Risk Factors. (World Health Organization, 2004).
Acknowledgements
We are extremely grateful to the following for their support and hard work in extracting and linking the datasets 
and providing access to them: Charlie Mayor (Data Safe Haven Manager), Alison Hamilton (Safe Haven Project 
Manager), Jonathan Todd (Head of Information Management), Imran Sadat (Data Manager) and Neil Hillen 
(Data Analyst).
Author contributions
F.H. and B.J. contributed equally and are joint-first authors. B.J. and J.P. conceptualised the study, interpreted 
the data, and wrote the first draft of the manuscript. F.H. analysed the data and wrote the first draft of the manu-
script. All other authors interpreted the data and critically revised the manuscript. All authors approved the final 
submitted version of the manuscript. B.J., F.H., and J.P. serve as the guarantor of the manuscript and accepts full 
responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision 
to publish. The corresponding author attests that all listed authors meet authorship criteria and that no others 
meeting the criteria have been omitted.
Funding
No external funding sources.
10
Vol:.(1234567890)
Scientific Reports |        (2021) 11:15278  | https://doi.org/10.1038/s41598-021-94630-6
www.nature.com/scientificreports/
Competing interests 
The authors declare no competing interests.
Additional information
Supplementary Information The online version contains supplementary material available at https:// doi. org/ 
10. 1038/ s41598- 021- 94630-6.
Correspondence and requests for materials should be addressed to J.P.P.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access  This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the 
Creative Commons licence, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from 
the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.
© The Author(s) 2021
